| pubmed-article:17922042 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C0877880 | lld:lifeskim |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C0016884 | lld:lifeskim |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:17922042 | lifeskim:mentions | umls-concept:C0303596 | lld:lifeskim |
| pubmed-article:17922042 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:17922042 | pubmed:dateCreated | 2007-11-16 | lld:pubmed |
| pubmed-article:17922042 | pubmed:abstractText | Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on (90)Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose (90)Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose (90)Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also (90)Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes. | lld:pubmed |
| pubmed-article:17922042 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17922042 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17922042 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17922042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17922042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17922042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17922042 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17922042 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17922042 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:WilsonKK | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:GisselbrechtC... | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:MartinelliGG | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:GianniA MAM | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:GlassBB | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:TillyHH | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:NaglerAA | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:SuredaAA | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:PettengellRR | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:HaiounCC | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:BethgeWW | lld:pubmed |
| pubmed-article:17922042 | pubmed:author | pubmed-author:DuarteR FRF | lld:pubmed |
| pubmed-article:17922042 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17922042 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:17922042 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17922042 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17922042 | pubmed:pagination | 1007-17 | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:meshHeading | pubmed-meshheading:17922042... | lld:pubmed |
| pubmed-article:17922042 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17922042 | pubmed:articleTitle | Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:17922042 | pubmed:affiliation | Institut d'Hématologie, Hôpital Saint-Louis, Paris, France. christian.gisselbrecht@sls.ap-hop-paris.fr | lld:pubmed |
| pubmed-article:17922042 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17922042 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:17922042 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17922042 | lld:pdb |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17922042 | lld:pdb |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17922042 | lld:pdb |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17922042 | lld:pdb |
